Abstract Purpose: To investigate the effect of 7-piperazine ethyl chrysin (PEC) on A-427 and A-549 lung cancer cell lines.
INTRODUCTION
Lung cancer is one of the leading causes of carcinoma-related deaths [1] . In 2008, about 10 lac cases of lung cancer were diagnosed throughout the world, resulting in 160,000 deaths in USA alone [2] . The regions most commonly affected by lung cancer include Southern America and Eastern parts of Asia and Europe [3] . The prognosis of lung cancer has improved over the years because of the development of comprehensive treatment strategies, amongst which is surgery. Although current treatments for lung cancer involve radical resection and chemotherapy (adjuvant), recurrence has been observed in majority of patients [3] [4] [5] . Thus, effective treatment for lung cancer is possible only through the discovery of novel anti-cancer drugs.
Apoptosis is the process of programmed cell death which plays an important role in removing unwanted cells from tissues [6, 7] . In cancer, cells undergo uncontrolled division because of the failure of apoptosis. The regulation of cell apoptosis involves phosphorylation of various factors, including ERK1/2 [8] . It is known that ERK ½ is a sub-group of the mitogen-activated protein kinases (MAPKs) which contribute to the survival of cancer cells [9] .
It has been reported that phosphorylation of ERK1/2 triggered apoptosis in various types of cancer carcinoma cells [10] . Decreased activation of MAPK ERK1/2 in murine melanoma cells has also been reported to suppress the growth of these cells [11] . Studies have also demonstrated that the anti-proliferative effect of 5, 7-dimethoxycoumarin involves inhibition of ERK1/2 phosphorylation in the melanoma cell line model [12] . The present study was aimed at investigating the effect of PEC on lung cancer cells, and its mechanism of action.
EXPERIMENTAL

Cell culture
The A-427 and A-549 lung cancer cell lines were purchased from the American Type Culture Collection (ATCC; Rockville, MD, USA), and were cultured in DMEM containing FBS (10 %), glutamine (2 mM), penicillin (100 U/mL) and streptomycin (100 μg/mL). The cells were cultured at 37 ˚C in an incubator in an atmosphere containing 5 % carbon dioxide.
Assay of cell proliferation
The proliferation of A-427 and A-549 cells after incubation with PEC or PD98059 (Selleck Chemicals LLC, Shanghai, China) was determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; SigmaAldrich) assay. The cell lines were cultured separately in 6-well plates (Nunc A/S Plastfabrikation, Roskilde, Denmark) in DMEM medium containing 10 % FBS at a density of 1 
Determination of apoptosis
Apoptosis in A-427 and A-549 cells was determined after 48 h of treatment with PEC using an annexin V-FITC/PI apoptosis assay kit (Major BioTech Co., Ltd., Shanghai, China). Untreated (control) and PEC-treated cells were subjected to trypsinization after harvesting and subsequently washed using phosphate-buffered saline (PBS). The washed cells were centrifuged for 10 min at 500 x g to remove the supernatant fraction. The resultant suspension was incubated for 20 min with annexin V-FITC (20 mL) and PI (20 mL) in the dark at room temperature, after which the cells were examined using flow cytometry (Beckman Coulter, Inc., Miami, FL, USA). The data obtained was analysed with WinMDI 2.9 (Purdue University Cytometry Laboratories, West Lafayette, USA). The experiments were performed in triplicate.
Matrigel invasion assay
Invasion of A-427 and A-549 cells was assessed using Transwell chambers pre-coated with 1 mg/mL Matrigel matrix (40 μL, BD Bioscience, Bedford, MA, USA). The cells (1 x 10 5 ) were trypsinized after 48 h of treatment with PEC, and subsequently put into the upper wells containing serum-free medium. The lower well contained medium with 10 % FBS alone. After incubation for 12 h, the cells on the Matrigel side of the chambers were cleaned using cotton swab. The cells were then fixed with methyl alcohol and subsequently stained with haematoxylin and eosin (H & E). The invaded cells were quantified with a light microscope in eight random fields at x200 magnification. The calculations were carried out in triplicate.
Western blot assay
Following 48 h of PEC treatment, the A-427 and A-549 cells were collected and washed with PBS. The cells were then lysed in cold lysis buffer and subsequently incubated for 30 min on ice. The lysates were centrifuged for 15 min at 12,000 x g at of 4 ˚C, and the protein concentration of the supernatant was determined using Bicinchoninic Acid Protein Assay kit (Pierce, Rockford, IL, USA) according to the instructions of the manufacturer. Protein samples (50 μg) were separated by electrophoresis on 12 % sodium dodecyl sulphate-polyacrylamide gel.
The samples were then transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA) by a semidry transfer system. The membranes were blocked using bovine serum albumin (BSA, 5 %) and Tris-buffered saline with Tween® 20 buffer at room temperature. Thereafter, the membranes were incubated with rabbit anti-human ERK and p-ERK polyclonal antibodies overnight at 4 ˚C. Then, they were washed twice with phosphatebuffered saline (PBS) and incubated for 1 h with horseradish peroxidase (HRP) conjugated secondary antibodies. The resultant immunoblots were visualized with enhanced chemiluminescence (LAS4000).
Statistical analysis
Data are presented as mean ± standard deviation (SD) of three experiments carried out independently. Analyses of data was made using Student's t-test and one-way analysis of variance (ANOVA). All statistical analysis were carried out with SPSS, version 15.0 (SPSS, Inc., Chicago, IL, USA). Differences were taken as statistically significant at p < 0.05.
RESULTS
Anti-proliferative effect of PEC
Exposure of A-427 and A-549 lung cancer cell lines to PEC led to significant reductions in their viabilities in time-and dose-dependent manners (Figure 1 ). The cell lines were incubated with PEC at doses of 2, 4, 6, 8 and 10 µM for 72 h, and cell viability was assessed after 24, 48 and 72 h of incubation. It was observed that reduction of cell viability was significant (p < 0.02) with PEC doses ≥ 4 µM at 48 h. In A-427 cells, viabilities on treatment with 2, 4, 6, 8 and 10 µM of PEC for 48 h were 99, 67, 43, 21 and 20 %, respectively, while the corresponding viabilities of A-549 cells at similar PEC doses were be 98, 62, 39, 18 and 19 %, respectively at 48 h (Figure 1) . However, the inhibition of viability of both cell lines was not significant at 24 h of treatment. 
PEC inhibited invasion in A-427 and A-549 lung cancer cells
Transwell assay was used to assess invasion of A-427 and A-549 lung cancer cells after incubation with PEC for 48 h. The results showed that PEC treatment inhibited invasion in both cell lines in a concentration-dependent manner (Figure 3) . Increase in the concentration of PEC from 2 to 8 µM significantly reduced the invasion potential of A-427 and A-549 cells. 
Effect of PEC on ERK1/2 activation
The activation of ERK1/2 was determined in A-427 and A549 cells by western blot assay after treatment with PEC at doses of 2, 4, 6, 8 and 10 µM for 48 h. It was observed that PEC treatment caused suppression of ERK1/2 activation in a concentration-dependent manner. Although the suppression of ERK1/2 activation was significant at PEC doses ≥ 4 µM, maximum inhibition was observed at 8 µM PEC (Figure 4) .
Effect of PD98059 on cell viability
It was found that PD98059 treatment inhibited viabilities of both A-427 and A-549 cells to degrees comparable with the inhibition caused by PEC ( Figure 5 ). These findings suggest that PEC inhibited viability of lung cancer cells by suppression of the activation of ERK1/2. 
DISCUSSION
Lung cancer is a challenge to clinicians, and has led to continuous studies aimed at developing more effective treatment strategies for the disease [13, 14] . The present study investigated the effect of PEC on lung cancer cell viability and demonstrated the mechanism involved. It was found that PEC treatment inhibited the viability of lung cancer cells and induced their apoptosis. Further studies showed that the mechanism of inhibition of lung cancer cell proliferation by PEC involved suppression of ERK1/2 activation. PEC treatment significantly inhibited the viability of lung cancer cells in concentration-and timedependent manners. Apoptosis is a cellular process associated with the destruction of unwanted cells, and it plays an important role in cancer treatment [6, 7] . The regulation of apoptosis involves phosphorylation of various factors amongst which is ERK1/2 [8] . The present study showed that in lung cancer cells, treatment with PEC led to a markedly high degree of induction of apoptosis.
It is well known that cancer cell proliferation is promoted by the activation of MAPK pathway which at the same time inhibits cancer cell apoptosis [15] . Since ERK1/2 is a member of MAPK family, its phosphorylation increases the rate of proliferation of cancer cells [16] . The results obtained in the current study showed that activation of ERK1/2 in lung cancer cells was decreased by incubation with PEC. These findings suggest that PEC inhibits viability and induces apoptosis in lung cancer cells by targeting ERK1/2 activation.
Incubation of the lung cancer cells with PD98059 also reduced cell viability to levels comparable with those brought about by PEC. These findings confirm that PEC exhibits its effect in lung cancer cells by targeting the ERK1/2 pathway.
CONCLUSION
The results of the present study demonstrate that treatment of lung cancer cells with PEC inhibits their viabiliy and induces their apoptosis via down-regulation of the activation of ERK1/2. Therefore, PEC may be suitable for clinical application in the management of lung cancer.
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